About Femtogenix
Femtogenix is a Healthcare company based in London (United Kingdom) founded in 2015. DNA-interactive payload molecules for ADCs are developed by Femtogenix. Femtogenix has raised $40.2 million across 2 funding rounds from investors including Research Corporation Technologies. The company has 14 employees. Femtogenix was last valued at $6 million in September 2015. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Aptamers. Its legal entity is Femtogenix Ltd.
Company details
Femtogenix, a spin-out company from Kings College London (KCL) is a drug discovery company focussed on developing DNA-interactive payload molecules for use in antibody-drug conjugates (ADCs). Its drug discovery platform claims to enable the design molecules which are capable of binding reversibly andor irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumor cells and when attached to antibodies, these potent cytotoxic agents can be delivered directly to tumors. It is currently looking for a partnership with pharmaceutical companies.
- Headquarters London, United Kingdom
- Employees 14
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Website femtogenix.com
- Legal Name Femtogenix Ltd.
- Net Profit-$3.52 M (USD)as on Mar 31, 2022
- Total Equity Funding$40.2M (USD)
in 2 rounds
- Latest Funding Round$36.63M (USD), Series B
Mar 2022
- Investors
- Employee Count14
Funding Insights of Femtogenix
Femtogenix has successfully raised a total of $40.2M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $36.63 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40.2M
- Total Rounds 2
- Last Round Series B — $36.63M
- First Round $3.57M
(Sep 2015)
- Investors Count 1
All 2 funding rounds of Femtogenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $36.63M | Series B | – | – | – |
| Sep 2015 | $3.57M | Series A | $6M | – |
| Date | Valuation | Stage |
|---|---|---|
| Sep 2015 | $6M | •••••••• |
Last known valuation $6M (Sep 2015). 1 investors in total: 1 institutional.
Investors in Femtogenix
Femtogenix has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research Corporation Technologies is engaged in licensing biomedical technologies. | rctech.com | Tucson, United States |
Investor details for Femtogenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Femtogenix
4 dated milestones of Femtogenix across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Femtogenix is founded.
- Funding First funding round of $3.6M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $36.6M.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Femtogenix (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Femtogenix
Complete news archive for Femtogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Femtogenix
Femtogenix was founded in 2015.
Femtogenix is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Femtogenix is a funded company, having raised a total of $40.2M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.57M, raised on Sep 2015.
Femtogenix has 14 employees.
Femtogenix, a spin-out company from Kings College London (KCL) is a drug discovery company focussed on developing DNA-interactive payload molecules for use in antibody-drug conjugates (ADCs). Its drug discovery platform claims to enable the design molecules which are capable of binding reversibly andor irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumor cells and when attached to antibodies, these potent cytotoxic agents can be delivered directly to tumors. It is currently looking for a partnership with pharmaceutical companies.
Femtogenix has 1 investor. Key investors include Research Corporation Technologies.
The valuation of Femtogenix is $6M as of Sep 2015.
Femtogenix operates through Femtogenix Ltd..